Ephedrine increases ventricular arrhythmias in conscious dogs after myocardial infarction  by Adamson, Philip B. et al.
E
i
P
E
O
U
t
w
t
p
U
f
fi
s
g
c
s
o
e
m
m
i
o
i
m
d
l
O
U
a
Journal of the American College of Cardiology Vol. 44, No. 8, 2004
© 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00
Pphedrine Increases Ventricular Arrhythmias
n Conscious Dogs After Myocardial Infarction
hilip B. Adamson, MD, FACC,*† Jennifer Suarez, BS,* Ethannah Ellis, BS,* Travis Kanaly, BS,*
milio Vanoli, MD*†‡
klahoma City, Oklahoma; and Pavia, Italy
OBJECTIVES This study examined the hypothesis that the sympathomimetic activity of ephedrine increases
the risk of lethal arrhythmias.
BACKGROUND The sympathomimetic amine, ephedrine, is used to augment physical performance and as a
weight loss aid, but little is known about the cardiovascular consequences in individuals with
ischemic heart disease.
METHODS Fifteen dogs at low risk for ventricular fibrillation (VF) during exercise and transient
myocardial ischemia 30 days after a small anterior myocardial infarction were retested after
five days of ephedrine use (Xenadrine, 0.4 mg/kg/day orally). To assess the effects of
ephedrine on cardiac autonomic control, baroreceptor reflex sensitivity (BRS), heart rate
(HR) variability, HR response to acute myocardial ischemia, and resting catecholamines were
measured before and after ephedrine. Dogs were used as their own control when possible.
RESULTS Nine of 15 animals had increased ventricular arrhythmias during ephedrine treatment (p 
0.01) and four had VF. Three dogs that had VF could not be resuscitated. Five animals with
increased arrhythmias during ephedrine treatment had none during a third exercise and
ischemia test after drug washout. Heart rates were higher after 30 s of myocardial ischemia
during ephedrine treatment (204  25 beats/min no drug vs. 218  26 beats/min with
ephedrine, p  0.03). All plasma catecholamines increased after ephedrine administration.
No changes in BRS, HR variability, or exercise HR were noted.
CONCLUSIONS Ephedrine increases ischemia-dependent arrhythmias at doses recommended in over-the-
counter preparations. Increased arrhythmia risk was associated with augmented ischemia-
dependent sympathetic reflex activation. (J Am Coll Cardiol 2004;44:1675–8) © 2004 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.07.041the American College of Cardiology Foundation
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ose of over-the-counter sympathomimetic amines, in-
ended to augment physical performance in athletes or as a
eight loss aid, is controversial, and there is little informa-
ion on potential risks (1). Cardiovascular symptoms com-
rise almost one-half of the adverse events reported to the
.S. Food and Drug Administration (FDA) (2) and range
rom cerebrovascular accidents to seizures and ventricular
brillation (VF) (2). Recently, the U.S. FDA banned the
ale of ephedrine-containing supplements (3), based on
rowing concerns about the adverse health effects of the
ompound when made available without physician supervi-
ion. However, systematic data on the cardiovascular effects
f ephedrine and, specifically, any potential arrhythmogenic
ffects are not available.
Sympathetic activation, as may occur with ephedrine use,
ay alter cardiac electrophysiology leading to an arrhyth-
ogenic trigger (4) in individuals with cardiac disease, even
f they are at relatively low arrhythmia risk. Even higher risk
f adverse cardiovascular events may occur in subjects with
schemic heart disease. Therefore, autonomic alterations
ay be the underlying mechanism for the sudden cardiac
eaths associated with ephedrine use in case reports. This
From the *Department of Physiology, †Department of Medicine, Cardiovascu-
ar Diseases, University of Oklahoma Health Sciences Center, Oklahoma City,
klahoma; and ‡Dipartimento di Cardiologia, Policlinico San Matteo, IRCCS e
niversità di Pavia, Pavia, Italy.r
Manuscript received June 2, 2004; revised manuscript received July 15, 2004,
ccepted July 20, 2004.tudy examined the hypothesis that ephedrine supplements,
sed in doses recommended in over-the-counter prepara-
ions, increase the relative risk of ischemia-dependent ven-
ricular arrhythmias in the presence of chronic ischemic
eart disease. This hypothesis was tested using a clinically
elevant canine model of sudden death in which two
eproducible populations of animals are produced, based on
heir relative risk of VF during exercise and transient
yocardial ischemia 30 days after myocardial infarction
MI) (5–8).
ETHODS
urgical instrumentation. Healthy mongrel dogs (weight
8 to 25 kg) were used for this study, and protocols for
urgical instrumentation have been published (6–8). Briefly,
uring general anesthesia, an anterior MI was created by a
wo-stage permanent ligation of the left anterior descending
oronary artery. Pacing leads were secured to the right
trium and ventricle, and a pneumatic vascular occluder and
0-MHz Doppler blood flow probe were implanted around
he left circumflex coronary artery. A catheter was placed in
he descending aorta for later evaluation of arterial pres-
ures. Instrumentation was exteriorized at the dorsum of the
eck.
Postoperative care was administered in a special high-
xygen-flow intensive care cage, and each dog immediately
eceived a short-acting analgesic (pentazocine lactate,
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nubain, 1 mg/kg intramuscularly). Dogs were allowed to
ecover for 30 days before any further experimentation. The
ocal Institutional Animal Care and Use Committee re-
iewed and approved all protocols. Guidelines on the use of
nimals in long-term research, as outlined by the U.S.
ational Institutes of Health, American Physiologic Soci-
ty, and American Heart Association, were strictly followed.
isk assessment for VF. After recovery from the acute MI
nd daily acclimation to the laboratory, each dog’s risk of
F was evaluated using a submaximal exercise test coupled
ith transient myocardial ischemia, according to previously
ublished methods (6–8). Dogs ran on a motorized tread-
ill starting at 3 mph at 0% incline and increasing every 3
in up to 4 mph at 12% incline, until the heart rate (HR)
eached a target range of 210 beats/min. At the target HR,
he circumflex occluder was inflated for 2 min; dogs con-
inued to run for the first minute, and the treadmill was
topped for the second minute.
Dogs that developed VF during the 2 min of transient
yocardial ischemia were allowed to lose consciousness and
ere then defibrillated. These dogs were labeled as “suscep-
ible” to sudden death. Dogs that did not develop VF were
abeled as “resistant” to sudden death. Arrhythmia risk
tatus was always confirmed with a second no-drug exercise
nd ischemia test documenting the initial risk status before
he animal entered the drug protocol. Only resistant dogs
ntered the study and were tested again to study the
otential pro-arrhythmic effect of ephedrine using internal
ontrol analysis. Two investigators (Drs. Adamson and
anoli) reviewed digitized electrocardiographic recordings
rom the entire 2 min of myocardial ischemia to determine
he incidence of ventricular arrhythmias, while blinded to
reatment status. Ventricular ectopy was classified as iso-
ated premature ventricular contractions (1 to 3 successive
entricular contractions), ventricular tachycardia (3 suc-
essive ventricular contractions), and VF. A final exercise
nd ischemia test was performed in surviving animals after
rug washout.
rug testing. Ephedrine (Xenadrine RFA-1; CYTODYNE
echnologies, Lakewood, New Jersey) was purchased over the
ounter from a local health food store. Each capsule contained
0 mg ephedrine, and dosing in this study followed the
abeling instructions provided with the product. The maximum
ose recommended was 100 mg/day for a healthy adult, not to
xceed 12 weeks. Initial recommended therapy was for 10 mg
wice daily (total 20 mg/day) and increased to 20 mg twice
Abbreviations and Acronyms
BRS  baroreflex sensitivity
FDA  Food and Drug Administration
HR  heart rate
MI  myocardial infarction
VF  ventricular fibrillationaily after one week in conjunction with physical workouts. dssuming a human weight of 80 kg, the maintenance dose
quates to 0.5 mg/kg/day. The dose chosen in this study was
.4 mg/kg/day in divided doses for five days.
utonomic testing. Baroreflex sensitivity (BRS) was mea-
ured in the first 10 dogs tested while the animals were
esting comfortably on a padded table. The blood pressure
ise in response to phenylephrine bolus (2 to 3 g/kg
ntravenously) was correlated to the RR-interval slowing,
nd a regression line was computed. The slope of the
egression line defined BRS, and only significant correla-
ions (R  90%) were used. Testing was performed at
aseline and after five days of ephedrine use.
Serum catecholamine levels were obtained from blood
rawn while the animals were resting comfortably on a
added table. Catecholamine levels were measured by the
linical laboratories at the University of Oklahoma Health
ciences Center.
tatistical analysis. A change in arrhythmia incidence was
efined as the development of premature ventricular con-
ractions, ventricular tachycardia, or VF during the 2 min of
ransient myocardial ischemia. The significance of arrhyth-
ia incidence was examined using the chi-square test.
hanges in cardiovascular parameters were tested using the
tudent t test for paired observations. An alpha level of p 
.05 was considered significant. Data are presented as the
ean value  SD, unless otherwise noted.
ESULTS
isk of VF. No dog had ventricular ectopy during the
nitial exercise and myocardial ischemia test. Nine of the 15
esistant dogs studied had increased ventricular arrhythmias
uring the exercise and ischemia test performed after five
ays of ephedrine therapy (p  0.01) and four of those
igure 1. Arrhythmia incidence during no-drug control (left), ephedrine
reatment (middle), and drug washout (right). The 60% increase in
rrhythmia incidence during ephedrine therapy was significant (p  0.02).
VC  premature ventricular contractions; VF  ventricular fibrillation;
T  ventricular tachycardia.eveloped VF (Fig. 1). Only one animal that developed VF
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one of the surviving animals had ventricular arrhythmias
hen re-tested after ephedrine washout.
In the no-drug exercise and myocardial ischemia test,
Rs averaged 199  23 beats/min at the onset of circum-
ex occlusion and increased slightly after 30 s of myocardial
schemia to 204  25 beats/min (p  0.1), reflecting the
ypical pattern of autonomic response to ischemia of resis-
ant dogs. After ephedrine, HRs immediately before coro-
ary occlusion were 188  38 beats/min (p  NS vs.
o-drug) and increased to 218  26 beats/min after 30 s of
cclusion (p 0.03 vs. no-drug test). Ephedrine use did not
hange BRS measurements (21 10 ms/mm Hg control vs.
7  9 ms/mm Hg after ephedrine, p  0.1). Corrected
T intervals, measured while the animals were standing on
he treadmill immediately before the onset of exercise, were
92  40 ms in no-drug conditions and 288  14 ms after
phedrine.
Serum catecholamines increased after ephedrine dosing,
s demonstrated in Figure 2. Most of the change in
atecholamines was accounted for by a fourfold increase in
orepinephrine (from 81.9  78.3 pg/ml [no-drug] to 345
200 pg/ml, p  0.0001).
ISCUSSION
his study demonstrates that ephedrine increases the risk of
schemia-dependent ventricular arrhythmias in the presence
f chronic ischemic heart disease. The data also provide
eaningful insights regarding ephedrine’s cardiovascular
ffects, which have not been assessed in clinical trials. First,
t recommended doses, ephedrine did not change the HR
esponse to graded exercise in subjects with a healed MI, but
t augmented the HR response to acute myocardial isch-
mia. There was also limited clinical evidence in normal
bese persons (9) of an exercise HR effect, but no data are
vailable in subjects with overt coronary disease. Heart rates
fter 30 s of coronary occlusion were significantly higher in
esistant dogs taking ephedrine, but did not increase to
igure 2. Serum catecholamine levels before (no drug; open bars) and after
reatment with ephedrine (hatched bars). Epi  epinephrine; Norepi 
orepinephrine; Total  total catecholamines. *p  0.001.evels characteristic of susceptible dogs (7). tThe mechanisms involved in the tachycardia response to
cute ischemia are primarily determined by acute activation
f sympathetic afferents resulting in decreased vagal and
ncreased sympathetic cardiac efferent activity (10). Ephed-
ine administration resulted in a four-fold increase in
irculating norepinephrine levels, suggesting that neural
ympathetic outflow was augmented. Because most of the
R response to moderate exercise is mediated by vagal
ithdrawal (11), it is not surprising that the HRs during
xercise in this and other studies were unaffected by ephed-
ine. However, when sympathetic reflexes were activated by
ransient myocardial ischemia, the cardio-acceleration was
ignificantly augmented by ephedrine’s effect on sympa-
hetic outflow. In this situation, ischemia-dependent ar-
hythmias were more likely to occur.
No previous animal studies testing potential pro-
rrhythmia with ephedrine are available, but a significant
olume of data are available documenting the fact that
ardiac sympathetic activation increases the risk of sudden
eath (4–8,12–14). Anecdotal reports to the U.S. FDA are
vailable, suggesting that cardiovascular events account for
lmost one-half of the adverse events reported with ephed-
ine (2), but the true incidence of cardiovascular complica-
ions cannot be determined from case reports alone. A
ongitudinal clinical trial designed to assess the safety of
phedrine-containing supplements would require large
umbers of subjects and will not likely occur.
Data from the present study may help this deficit in
vidence by predicting that individuals with clinical or
ubclinical ischemic heart disease are at high risk of ven-
ricular arrhythmias and sudden death during treatment
ith ephedrine. The animal model used in this study is
nown to have clinical relevance for examining the mecha-
isms of sudden death (6). Cardiac autonomic assessment
ith BRS and HR variability, to predict sudden death risk,
as first described in this model (7) and subsequently
linically validated (14). Furthermore, interventions that
revent VF in this model, such as beta-blockers, sympa-
hectomy, amiodarone, and d,l-sotalol, effectively reduce
rrhythmic mortality in clinical populations (6). Finally,
nterventions that do not prevent VF in this model are
neffective in clinical populations, such as dofetilide, azim-
lide, and d-sotalol (6).
onclusions. Ephedrine use in animals with chronic isch-
mic heart disease is associated with an increased risk of
entricular arrhythmias during acute ischemic events. The
xperimental setting used in this study portrays a complex
ondition of acute ischemia coupled with a healed MI.
owever, the 60% increase in ventricular arrhythmias in the
ow-risk animals used in this study creates a strong warning
or less severe conditions, specifically considering the wide-
pread incidence of asymptomatic coronary artery disease.
his is important, because up to 44% of sudden deaths arehe first manifestation of ischemic heart disease (15).
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